First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: TAS266
Frequency and characteristics of Dose limiting toxicities at each dose level, 2 years
Type, frequency, and severity of AEs, changes in laboratory and clinical assessments, 2 years|TAS266 serum concentrations and PK parameters: Cmax, Tmax, AUC0-tlast, Tlast, T1/2 and accumulation ratio of TAS266, 1 Treatment Cycle = 28 days,) assuming maximum 6 cycles of treatment, 8 timepoints each for Cycles 1 and 2, prior to dosing on Day 1 of Cycles 3, 4, 5 and 6, at End of Treatment|Presence and concentration of anti-TAS266 antibodies, 2 Years|Tumor response, 2 Years
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.